-

CytRx to Hold Town Hall for Stockholders on Thursday, January 20th

Town Hall to be Led by New CEO Dr. Stephen Snowdy

LOS ANGELES--(BUSINESS WIRE)--CytRx Corporation (OTCQB: CYTR) (“CytRx” or the “Company”), a specialized biopharmaceutical company focused on research and development for the oncology and neurodegenerative disease categories, today announced that it will hold a town hall for stockholders on Thursday, January 20, 2022 at 4:30 PM Eastern. The town hall will be led by the Company’s Chief Executive Officer, Dr. Stephen Snowdy, and include a question-and-answer session. The town hall can be accessed here.

A recording of the town hall will be available on CytRx's website under the News & Events section following the event.

About CytRx

CytRx Corporation (OTCQB: CYTR) is a biopharmaceutical company with expertise in discovering and developing new therapeutics principally to treat patients with cancer and neurodegenerative diseases. CytRx’s most recent advanced drug conjugate, aldoxorubicin, is an improved version of the widely used anti-cancer drug doxorubicin and has been out-licensed to ImmunityBio, Inc. In addition, CytRx’s drug candidate, arimoclomol, was sold to Orphazyme A/S in exchange for milestone payments and royalties. Orphazyme is developing arimoclomol in two indications, including Niemann-Pick disease Type C (NPC), and Gaucher disease. CytRx Corporation’s website is www.cytrx.com.

Contacts

Longacre Square Partners
Greg Marose / Bela Kirpalani
cytrx@longacresquare.com

Industry:

CytRx Corporation

OTCQB:CYTR
Release Versions
English

Contacts

Longacre Square Partners
Greg Marose / Bela Kirpalani
cytrx@longacresquare.com

More News From CytRx Corporation

CytRx Corporation Relaunches as LadRx Corporation

LOS ANGELES--(BUSINESS WIRE)--CytRx Corporation (OTCQB: CYTR) (“CytRx” or the “Company”), a biopharmaceutical innovator focused on research and development of life-saving cancer therapeutics, announces that it is relaunching as LadRx Corporation. Chief Executive Officer Stephen Snowdy, PhD commented, “Since January of 2022, the Company has taken several steps towards change and renewal. We started by bringing in new board member Dr. Jennifer Simpson in 2021, and bringing new leadership into the...

European Patent Office Awards CytRx Key Patent

LOS ANGELES--(BUSINESS WIRE)--CytRx Corporation (OTCQB: CYTR) (“CytRx” or the “Company”), a biopharmaceutical innovator focused on research and development of life-saving cancer therapeutics, today announced it has been awarded a key patent by the European Patent Office, and that the period for parties to oppose the patent has lapsed without opposition. European Patent No. 3310800 covers the incorporation of the LADR backbone in a variety of drug compounds. The LADR backbone is attached to acti...

CytRx Welcomes Cary J. Claiborne to the CytRx Board of Directors

LOS ANGELES--(BUSINESS WIRE)--CytRx Corporation (OTCQB: CYTR) (“CytRx” or the “Company”), a biopharmaceutical innovator focused on research and development of life-saving cancer therapeutics, welcomes Mr. Cary J. Claiborne to the CytRx Board of Directors (the “Board"). Mr. Claiborne brings to CytRx a wealth of experience in public company governance, finance and operational management. Mr. Claiborne is the Chief Operating Officer at Adial Pharmaceuticals, Inc. (“Adial”), a public biopharmaceuti...
Back to Newsroom